1 / 7

Cost-Effectiveness of Treatment Strategies for Comorbid Diabetes and Dyslipidemia

This study examines the prevalence of dyslipidemia and diabetes mellitus in a managed care setting and highlights the economic costs associated with these comorbidities. Patients with diabetes often have cardiovascular comorbidities, which contribute to the high healthcare costs of diabetes. Age, glycemic control, and cardiometabolic risk factors are important drivers of healthcare spending in diabetes.

lillies
Download Presentation

Cost-Effectiveness of Treatment Strategies for Comorbid Diabetes and Dyslipidemia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cost-Effectiveness of Treatment Strategies for Comorbid Diabetes and Dyslipidemia Part 1

  2. Prevalence of Dyslipidemia and Diabetes Mellitus in Managed Care • Kaiser Permanente, Northern California • 2.1 million adult members • Adjusted prevalence of each medical condition • Dyslipidemia = 35.6% • Diabetes mellitus* = 8.7% • Hypertension = 27.6% • Prevalence of comorbidities increased with age *Data represents both type 1 and type 2 diabetes Selby JV, et al. Am J Manag Care. 2004;10(Pt 2):163-170.

  3. Patients With Diabetes Mellitus Often Have Cardiovascular Comorbidities All patients with diabetes mellitus 56% have comorbid dyslipidemia and hypertension 74% have comorbid hypertension 73% have comorbid dyslipidemia n=137,745 patients with diabetes mellitus Selby JV, et al. Am J Manag Care. 2004;10(Pt 2):163-170.

  4. Economic Costs of Diabetes in the United States, 2007 $58 billion $116 billion Comorbid CVD is the largest contributor to the costs of diabetes2 Total Annual Costs1: $174 billion • Direct medical costs • Diabetes care: $27 billion • Diabetes-related conditions: $58 billion • General medical costs: $31 billion • Indirect costs • Absenteeism: $2.6 billion • Presenteeism: $20 billion • Productivity loss for those not in work force: $0.8 billion • Permanent disability: $7.9 billion • Premature mortality: $26.9 billion 1. ADA. Diabetes Care.2008;31(3):596–615. 2. ADA. Diabetes Care. 2009;32(suppl 1):S13-S61.

  5. Factors That Drive Healthcare Spending in Diabetes Age Patients >50 years incur 81% of total direct costs Patients with A1C of 10% incur $1,500 to $5,000 more in incremental 3-year costs vs those with A1C of 6% Glycemic control Top 10% of high-cost patients who incur 60% of overall costs are more likely to have complications, especially CVD Complications Cardiometabolic risk factors Patients with obesity ± dyslipidemia incur $700 to $2,000 more in incremental annual costs Hoerger TJ, Ahmann AJ. J Manag Care Pharm. 2008;14(suppl S-c):S2-S14.

  6. CVD Drives Healthcare Costs in Patients With Diabetes Medical costs Pharmaceutical costs Total Mean Annual Costs, $ Low = no risk factors, signs and symptoms, or evidence of CVD; Moderate = use of antihypertensive or lipid-lowering medications or 1 CVD risk factor; High = stable CVD; Very High = unstable CVD. Rosenzweig JL, et al. Am J Manag Care. 2002;8(11):950-958.

  7. Macrovascular Disease Triples Healthcare Costs in Patients With Diabetes Claims data analyses of a commercial HMO shows that inpatient costs relative to total healthcare costs are much larger in patients with MVD (44%) than those without MVD (17%) MVD=macrovascular disease Gandra SR, et al. J Manag Care Pharm. 2006;12(7):546-554.

More Related